내분비 검사 시장 예측 : 검사 유형별, 기술, 최종사용자, 지역별 분석(-2034년)

According to Stratistics MRC, the Global Endocrine Testing Market is accounted for $3.8 billion in 2026 and is expected to reach $8.3 billion by 2034 growing at a CAGR of 10.4% during the forecast period. Endocrine testing involves the assessment of hormone levels in the body's endocrine system, which regulates various physiological functions. By determining the hormone concentrations in blood, urine, or saliva samples, this diagnostic procedure aids in the identification of hormonal imbalances or disorders. Thyroid hormones, cortisol, insulin, and reproductive hormones like testosterone and estrogen are among the hormones that are frequently tested.

According to the World Health Organization (WHO) in March 2022, 650 million adults, 340 million teenagers, and 39 million children are obese around the world and the number is still rising.

Market Dynamics:

Driver:

Rise in disorders associated with lifestyle

The increase in the endocrine related disorders is partly attributed to alterations in lifestyle patterns, like sedentary lifestyle and unhealthy eating habits. The need for diagnostic tests that can precisely identify hormonal imbalances and offer early diagnosis of such conditions has increased. Additionally, the market for endocrine testing is expected to grow as medical professionals look for cutting-edge instruments to handle the difficulties in diagnosing lifestyle-related illnesses, stressing the need for accurate and timely hormone evaluations for efficient illness treatment.

Restraint:

Errors in specimen collection

Appropriate specimen collection, storage, and transportation are critical to guaranteeing accurate hormone level measurements. Problems like incorrect sample handling, contamination, or transportation delays can damage the samples' integrity and produce inaccurate test results. Variability in outcomes may also be caused by different healthcare settings using inconsistent methods for data collection. However, it is imperative that these sample-related issues are resolved in order to preserve the accuracy and consistency of endocrine tests, underscoring the necessity of uniform procedures and training for healthcare personnel.

Opportunity:

Companion diagnostics

Companion diagnostics present a unique opportunity in the endocrine testing market by offering tailored solutions for personalized treatment in endocrine disorders. By identifying particular biomarkers or genetic markers, these diagnostics assist medical professionals in matching patients with the most appropriate treatments. This precision approach minimizes side effects, maximizes therapeutic interventions, and improves treatment outcomes in endocrine testing. Moreover, this customized approach enhances patient care while also adding to the general efficacy and affordability of endocrine-related healthcare.

Threat:

Intellectual property challenges

Intellectual property issues are brought about by the creation and application of novel testing techniques, biomarkers, and diagnostic technologies. Businesses that spend money on R&D have to worry about patent infringement because rivals might try to copy or enhance proprietary testing methods. The dynamic nature of endocrine diagnostics gives rise to inquiries concerning the extent and legitimacy of existing patents, thereby engendering conflicts concerning intellectual property rights.

Covid-19 Impact:

The endocrine testing market has been greatly affected by the COVID-19 pandemic. The endocrine system is one of the organs that the virus can affect, so there is a greater need for endocrine tests to evaluate hormonal imbalances and complications in infected individuals. The endocrine testing industry has seen a surge in innovation and research due to the need for comprehensive diagnostic solutions to comprehend the virus's impact on hormone levels. The focus on diagnosing and treating endocrine disorders has kept the endocrine testing market growing during these difficult times, despite disruptions in the healthcare system.

The immunoassay segment is expected to be the largest during the forecast period

The immunoassay segment has grown substantially because of its high sensitivity and specificity in identifying hormones and associated biomarkers. The need for precise and effective diagnostic techniques has been fueled by the rising incidence of endocrine disorders, including diabetes and thyroid issues. Furthermore, automation, the creation of new assays, and technological developments has all contributed to this segment's growth.

The insulin test segment is expected to have the highest CAGR during the forecast period

Insulin test segment is expected to have the highest CAGR during the forecast period. Insulin tests are in high demand because diabetes management greatly depends on insulin level monitoring. The sector's growth has also been aided by developments in testing technologies, such as faster and more accurate assays. Insulin test adoption has also been influenced by the growing emphasis on personalized medicine and the early detection of diabetes.

Region with largest share:

Asia Pacific region dominated the largest share due to the increasing prevalence of endocrine disorders, rising awareness about hormonal health, and advancements in healthcare infrastructure. The adoption of modern diagnostic technologies and the expansion of healthcare facilities contribute to the market's upward trajectory. Additionally, heightened investments in research and development, coupled with proactive government initiatives, further fuel the market's expansion.

Region with highest CAGR:

The market has grown profitably in North America due to rising incidence of endocrine disorders and increased public awareness of early disease detection. The region's high healthcare spending and well-established healthcare infrastructure have further stimulated market growth. Furthermore, increased R&D spending in the biotechnology and pharmaceutical industries has sparked innovation in endocrine testing techniques, which has further fuelled the regional growth.

Key players in the market

Some of the key players in Endocrine Testing market include AB Sciex, Abbott Laboratories, Agilent Technologies Inc., Beckman Coulter, Inc., Biomedical Technologies Limited, BioMerieux SA, Bio Rad Laboratories, Inc. , Danaher Corporation, DH Tech. Dev. Pte. Ltd., DiaSorin SpA, F. Hoffmann-La Roche Ltd, Hologic Inc., Laboratory Corporation of America Holdings, Ortho Clinical Diagnostics, Qiagen N.V., Quest Diagnostics, Siemens Healthineers AG and Thermo Fisher Scientific.

Key Developments:

In December 2023, Roche announced the entry into a definitive merger agreement to acquire Carmot Therapeutics, Inc, a privately owned US company based in Berkeley, California. Carmot's R&D portfolio includes clinical stage subcutaneous and oral incretins with best-in-class potential to treat obesity in patients with and without diabetes, as well as a number of preclinical programs.

In May 2023, Hologic Inc., a global leader in women's health, announced a partnership with recently drafted NFL cornerback Kelee Ringo and his mother, breast cancer survivor Tralee Hale, to educate women on the importance of prioritizing annual mammograms and other key health screenings.

Test Types Covered:

• Human Chorionic Gonadotropin Hormone Test
• Prolactin Test
• Progesterone Test
• Insulin Test
• Thyroid Stimulating Hormone Test
• Luteinizing Hormone Test
• Dehydroepiandrosterone Sulfate Test
• Estradiol Test
• Cortisol Test
• Testosterone Test
• Follicle Stimulating Hormone Test
• Other Test Types

Technologies Covered:

• Nucleic Acid Based
• Mass Spectroscopy
• Chromatography
• Immunoassay
• Other Technologies

End Users Covered:

• Clinical Laboratories
• Diagnostic Centers
• Hospitals
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Technology Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Endocrine Testing Market, By Test Type

• 5.1 Introduction
• 5.2 Human Chorionic Gonadotropin Hormone Test
• 5.3 Prolactin Test
• 5.4 Progesterone Test
• 5.5 Insulin Test
• 5.6 Thyroid Stimulating Hormone Test
• 5.7 Luteinizing Hormone Test
• 5.8 Dehydroepiandrosterone Sulfate Test
• 5.9 Estradiol Test
• 5.10 Cortisol Test
• 5.11 Testosterone Test
• 5.12 Follicle Stimulating Hormone Test
• 5.13 Other Test Types

6 Global Endocrine Testing Market, By Technology

• 6.1 Introduction
• 6.2 Nucleic Acid Based
• 6.3 Mass Spectroscopy
• 6.4 Chromatography
• 6.5 Immunoassay
• 6.6 Other Technologies

7 Global Endocrine Testing Market, By End User

• 7.1 Introduction
• 7.2 Clinical Laboratories
• 7.3 Diagnostic Centers
• 7.4 Hospitals
• 7.5 Other End Users

8 Global Endocrine Testing Market, By Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 US
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 Italy
  • 8.3.4 France
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 New Zealand
  • 8.4.6 South Korea
  • 8.4.7 Rest of Asia Pacific
• 8.5 South America
  • 8.5.1 Argentina
  • 8.5.2 Brazil
  • 8.5.3 Chile
  • 8.5.4 Rest of South America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 Qatar
  • 8.6.4 South Africa
  • 8.6.5 Rest of Middle East & Africa

9 Key Developments

• 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 9.2 Acquisitions & Mergers
• 9.3 New Product Launch
• 9.4 Expansions
• 9.5 Other Key Strategies

10 Company Profiling

• 10.1 AB Sciex
• 10.2 Abbott Laboratories
• 10.3 Agilent Technologies Inc.
• 10.4 Beckman Coulter, Inc.
• 10.5 Biomedical Technologies Limited
• 10.6 BioMerieux SA
• 10.7 Bio Rad Laboratories, Inc.
• 10.8 Danaher Corporation
• 10.9 DH Tech. Dev. Pte. Ltd.
• 10.10 DiaSorin SpA
• 10.11 F. Hoffmann-La Roche Ltd
• 10.12 Hologic Inc.
• 10.13 Laboratory Corporation of America Holdings
• 10.14 Ortho Clinical Diagnostics
• 10.15 Qiagen N.V.
• 10.16 Quest Diagnostics
• 10.17 Siemens Healthineers AG
• 10.18 Thermo Fisher Scientific